Bharat Biotech urges Centre to include intranasal Covid vaccine in CoWIN portal

Bharat Biotech has requested the central government to include its intranasal COVID19 vaccine iNCOVACC in CoWIN portal to enable the recipients of the jab to get vaccination certificateThe company sources said Bharat Biotech is currently holding discussions with international potential partners who have approached the company for manufacturing and distribution of the intranasal vaccine globallySince iNCOVACC has been approved for Restricted use under emergency situationiquest and vaccine recipients will require vaccine certificates we have requested the government to include iNCOVACC in the COWIN portal Once this is enabled India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID the sources told PTICurrently Bharat Biotechs Covaxin Serum Institutes Covishield and Covovax Russian Sputink V and Biological E Ltds Corbevax are listed in the CoWin portalAlso Read Maharashtra reports 45 new Covid19 cases one death active tally at 217The vaccine maker on September 6 announced that its iNCOVACC BBV154 worlds first intranasal COVID19 vaccine has received approval from Drugs Controller General of India under Restricted Use in Emergency Situation for ages 18 and aboveThere have been no requests for procurement from state or central governments sources further saidThe citybased vaccine maker also plans to export iNCOVACC to other countries once it gets approvals from the respective nations sources addediNCOVACC BBV154 has also received approval from the Central Drugs Standard Control Organisation CDSCO under Restricted Use in Emergency Situation for ages 18 and above in India for heterologous booster dosesThe vaccine was developed in partnership with Washington University St Louis which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacyThe vaccine candidate underwent Phases I II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal dropsPhaseIII trials were conducted for safety immunogenicity in approximately 3100 subjects at 14 trial sites across IndiaThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever